These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 20598622)

  • 1. Classifying risk factors for dyskinesia in Parkinson's disease.
    Sharma JC; Bachmann CG; Linazasoro G
    Parkinsonism Relat Disord; 2010 Sep; 16(8):490-7. PubMed ID: 20598622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adenosine receptors and L-DOPA-induced dyskinesia in Parkinson's disease: potential targets for a new therapeutic approach.
    Blandini F
    Exp Neurol; 2003 Dec; 184(2):556-60. PubMed ID: 14769348
    [No Abstract]   [Full Text] [Related]  

  • 3. Risk factors in development of motor complications in Chinese patients with idiopathic Parkinson's disease.
    Kum WF; Gao J; Durairajan SS; Man SC; Xie LX; Lu JH; Fong WL; Li M
    J Clin Neurosci; 2009 Aug; 16(8):1034-7. PubMed ID: 19428256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk and course of motor complications in a population-based incident Parkinson's disease cohort.
    Bjornestad A; Forsaa EB; Pedersen KF; Tysnes OB; Larsen JP; Alves G
    Parkinsonism Relat Disord; 2016 Jan; 22():48-53. PubMed ID: 26585090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical pattern and risk factors for dyskinesias following fetal nigral transplantation in Parkinson's disease: a double blind video-based analysis.
    Olanow CW; Gracies JM; Goetz CG; Stoessl AJ; Freeman T; Kordower JH; Godbold J; Obeso JA
    Mov Disord; 2009 Feb; 24(3):336-43. PubMed ID: 19006186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of levodopa dose and body weight on dyskinesia in a prevalent population of people with Parkinson's disease.
    Walker RW; Howells AR; Gray WK
    Parkinsonism Relat Disord; 2011 Jan; 17(1):27-9. PubMed ID: 21051272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Levodopa-induced belly dancer's dyskinesias in Parkinson's disease: report of one case.
    Carecchio M; Collini A; Comi C; Cantello R; Bhatia KP; Monaco F
    Mov Disord; 2010 Aug; 25(11):1760-2. PubMed ID: 20645401
    [No Abstract]   [Full Text] [Related]  

  • 8. Dyskinesias predict the onset of motor response fluctuations in patients with Parkinson's disease on L-dopa monotherapy.
    Mazzella L; Yahr MD; Marinelli L; Huang N; Moshier E; Di Rocco A
    Parkinsonism Relat Disord; 2005 May; 11(3):151-5. PubMed ID: 15823479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. l-Dopa-induced dyskinesia-clinical presentation, genetics, and treatment.
    Prashanth LK; Fox S; Meissner WG
    Int Rev Neurobiol; 2011; 98():31-54. PubMed ID: 21907082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial.
    Goetz CG; Damier P; Hicking C; Laska E; Müller T; Olanow CW; Rascol O; Russ H
    Mov Disord; 2007 Jan; 22(2):179-86. PubMed ID: 17094088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimizing long-term therapy for Parkinson disease: options for treatment-associated dyskinesia.
    Stacy M; Galbreath A
    Clin Neuropharmacol; 2008; 31(2):120-5. PubMed ID: 18382184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Levodopa-dyskinesia incidence by age of Parkinson's disease onset.
    Kumar N; Van Gerpen JA; Bower JH; Ahlskog JE
    Mov Disord; 2005 Mar; 20(3):342-4. PubMed ID: 15580606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Dyskinesia in Parkinson's disease--major clinical features, aetiology, therapy].
    Ellrichmann G; Russ H; Müller T
    Fortschr Neurol Psychiatr; 2007 Jul; 75(7):387-96. PubMed ID: 17443441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Dyskinesia caused by L-DOPA].
    Derkinderen P; Vidailhet M
    Rev Neurol (Paris); 2002 Dec; 158 Spec no 1():S92-101. PubMed ID: 12690668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levodopa-associated dyskinesia risk among Parkinson disease patients in Olmsted County, Minnesota, 1976-1990.
    Van Gerpen JA; Kumar N; Bower JH; Weigand S; Ahlskog JE
    Arch Neurol; 2006 Feb; 63(2):205-9. PubMed ID: 16476808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rating scales for dyskinesias in Parkinson's disease.
    Goetz CG
    Mov Disord; 1999; 14 Suppl 1():48-53. PubMed ID: 10493403
    [No Abstract]   [Full Text] [Related]  

  • 17. Propofol Withdrawal Dyskinesia in a Parkinson's Disease Patient with Levodopa-Induced Dyskinesia.
    Nakajima A; Iwamuro H; Tokugawa J; Odo M; Shimo Y
    Can J Neurol Sci; 2023 Mar; 50(2):322-323. PubMed ID: 35115074
    [No Abstract]   [Full Text] [Related]  

  • 18. [Motor fluctuations and dyskinesias in Parkinson's disease: variables that discriminate both complications in a sample of 285 patients].
    Gómez JC; Rouco I; Velasco F; Tijero B; Garamendi I; Lezcano E; Zarranz JJ
    Neurologia; 2008 Oct; 23(8):494-8. PubMed ID: 18770057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Levodopa pharmacokinetics and dyskinesias: are there sex-related differences?
    Martinelli P; Contin M; Scaglione C; Riva R; Albani F; Baruzzi A
    Neurol Sci; 2003 Oct; 24(3):192-3. PubMed ID: 14598082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Social and economic cost of L-Dopa-induced dyskinesias in patients with Parkinson's disease].
    Maurel F; Lilliu H; Le Pen C
    Rev Neurol (Paris); 2001 May; 157(5):507-14. PubMed ID: 11438770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.